Global Injectable Drugs for Diabetes Market Revenue, Industry Growing Demand, Size, Share and Forecast – 2028

The global injectable drug for diabetes market is anticipated to grow at a significant CAGR 5% during the forecast period (2022-2028). The increase in type 2 diabetes has created a demand for the development of new drugs for its treatment which in turn drives the global injectable drug for diabetes market growth. The leading pharmaceutical companies are focusing on the development of drugs for type 2 diabetes treatment. Therefore, the market growth is driven by the strong focus of the pharmaceutical companies and research organizations on the R&D of drugs for injectable drugs for diabetes creating a strong medicine for effective treatments.

In December 2019, FDA approved new drugs such as canagliflozin and dapagliflozin for the treatment of diabetes will create many opportunities for new and existing athletes in the global injectable drug for diabetes market. Increasing number of people with diabetes, technological advancement, and increasing access to developing regions are key factors, which could improve the growth of the global drug market during the analysis period. Additionally, type 2 diabetes mellitus for about 90.0% of all diabetes cases and as a result of this increase in patients with diabetes, the market for injectable drugs for diabetes is expected to grow significantly. Furthermore, with the growing popularity of online pharmacies the drug supply chain in the drug delivery sector is expected to improve significantly and with these developments, the global injectable drug for diabetes market is expected to rise in the forecast period.

Key players in the market include GlaxoSmithKline Plc., Merck & Co., Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Dr. Reddy’s laboratories ltd, Lupin ltd, and Pfizer Inc. among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in January 2020, the US FDA approved Trijardy XR (empagliflozin / linagliptin/metformin hydrochloride long-acting pill) to lower blood sugar in adults with type 2 diabetes, which can be increased the growth of injectable drugs for diabetes market.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Drug Type
  • By Application
  • By Distribution Channel
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape-GlaxoSmithKline Plc, Merck & Co., Inc., Boehringer Ingelheim Pharmaceuticals, Inc., and Takeda Pharmaceutical Co. Ltd., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Injectable Drug for Diabetes Market Report by Segment

By Drug Type

• Oral Anti-diabetic Drugs
• Insulin Injectable Drug
• Non-insulin Injectable Drugs
• Combination Drugs

By Application

• Type 1 Diabetes
• Type 2 Diabetes

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Injectable Drug for Diabetes Market Report by Region

North America

• US
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa